ACCELERATE VACCINE INTRODUCTION – PNEUMOCOCCAL VACCINE
Strategic Demand Forecast (Required Supply)
Version 0.1 – updated as per July 2009
Published – 07 August 2009

This version 0.1 is issued in accordance with the AVI Forecasting Standard Operating Procedure that foresees the possibility for intermediate updates between official versions when changes in demand exceed predefined thresholds.

Pneumococcal Vaccine - AMC Required Supply (72 GAVI eligible countries)

Discretion: Except for countries which have already applied to GAVI for support for introduction of Pneumococcal Vaccines or are in the process of doing so, this forecast reflects the best possible estimates on countries’ expected time of introduction. The forecasted timeline for future introductions is not subject to approval by country representatives and, as such, does not constitute any commitment or obligation for any of the countries.

CHANGES VS. VERSION 0 (published in June 2009)
- DRC introduction delayed.
- India buffer stocks staggered aligned with state introduction.

KEY ASSUMPTIONS
- Available financing for the entire forecast duration for product purchase and introduction expenses; no changes in eligibility criteria; sufficient production capacity to meet demand; all prequalified products meet or exceed TPP and have suitable presentation; no impact/resolution of PAHO single price clause.
- Successful cold chain up scaling at central & local level in all countries where required.

Source: SVS sub team

- Introduction 12 months after application; 60 countries introducing by 2015; 21 countries in 2010 (8 already approved, 3 from May 2009 application, 10 out of applications expected in September 2009).
• Large countries: Pakistan and Nigeria to introduce in second half of 2011; India phased introduction starting in 2014 financed from local government; Indonesia introduction in 2014. 
  
  **Source:** WHO New & Underused Vaccine Introduction (NUVI) regional calls and other input

• 2 years uptake (time to reach peak coverage) for all countries except India (6 years), Nigeria, Pakistan and Indonesia (4 years).
  
  **Source:** HepB mono introduction analogue

• PCV3 (3rd dose) coverage projected to increase up to 90%.
  
  **Source:** SVS sub team projection based on DTP3 WHO-UNICEF Best Estimate

• Wastage = 10% based on a 2 doses vial, Buffer stocks = 25% of one year full supply. **Source:** GAVI Secretariat

• Population, crude birth rate & infant mortality rates as per medium variant.
  
  **Source:** 2008 UN population prospect

---

**UNICEF SUPPLY DIVISION WILL ISSUE A CALL FOR OFFERS WITHIN 20 IBRD BUSINESS DAYS AFTER PUBLICATION OF THIS FORECAST ON THE AMC WEBSITE.**

---

Note – Rwanda and Gambia introduction in 2009 benefits from donated product thus does not generate any supply requirement

---

**Contacts:**

For information related to this Strategic Demand Forecast: smalvolti@path.org

For information related to the AMC: amc@gavialliance.org